
Mohammed s Alesawy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2013220/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 573-591.	5.2	23
2	Design, synthesis, in silico ADMET, docking, and antiproliferative evaluations of [1,2,4]triazolo[4,3―c]quinazolines as classical DNA intercalators. Archiv Der Pharmazie, 2022, , e2100412.	4.1	8
3	Antiproliferative evaluations of triazoloquinazolines as classical DNA intercalators: Design, synthesis, ADMET profile, and molecular docking. Archiv Der Pharmazie, 2022, 355, e2100487.	4.1	5
4	Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2′-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs. Molecules, 2022, 27, 2287.	3.8	34
5	Triazoloquinazoline derived classical DNA intercalators: Design, synthesis, in silico ADME profile, docking, and antiproliferative evaluations. Archiv Der Pharmazie, 2022, 355, e2100506.	4.1	7
6	Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2. Bioorganic Chemistry, 2022, 123, 105770.	4.1	48
7	Ligand-based design and synthesis of <i>N'</i> -Benzylidene-3,4-dimethoxybenzohydrazide derivatives as potential antimicrobial agents; evaluation by <i>inÂvitro</i> , <i>inÂvivo, and in silico</i> approaches with SAR studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1098-1119.	5.2	27
8	Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: <i>in-vitro</i> anticancer evaluation and <i>in-silico</i> studies. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1903-1917.	5.2	64
9	New [1,2,4]triazolo[4,3â€ <i>c</i>]quinazoline derivatives as vascular endothelial growth factor receptorâ€2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation. Archiv Der Pharmazie, 2022, 355, .	4.1	6
10	Design and discovery of new 1,2,4â€ŧriazolo[4,3â€ <i>c</i>]quinazolines as potential DNA intercalators and topoisomerase II inhibitors. Archiv Der Pharmazie, 2021, 354, e2000237.	4.1	51
11	[1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4′,3′-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies. Bioorganic and Medicinal Chemistry, 2021, 30, 115958.	3.0	46
12	In Silico Studies of Some Isoflavonoids as Potential Candidates against COVID-19 Targeting Human ACE2 (hACE2) and Viral Main Protease (Mpro). Molecules, 2021, 26, 2806.	3.8	46
13	Design and synthesis of new 4-(2-nitrophenoxy)benzamide derivatives as potential antiviral agents: molecular modeling and <i>in vitro</i> antiviral screening. New Journal of Chemistry, 2021, 45, 16557-16571.	2.8	46
14	In Silico Screening of Semi-Synthesized Compounds as Potential Inhibitors for SARS-CoV-2 Papain-like Protease: Pharmacophoric Features, Molecular Docking, ADMET, Toxicity and DFT Studies. Molecules, 2021, 26, 6593.	3.8	35
15	Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists. Bioorganic and Medicinal Chemistry, 2017, 25, 4723-4744.	3.0	72